Amsterdam Molecular Therapeutics AMT Holding NV, which develops gene-based therapies for orphan diseases, raised €50 million in an initial public offering on the Euronext Amsterdam stock exchange. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
